Federated Hermes Inc. Reduces Stock Position in Xencor, Inc. (NASDAQ:XNCR)

Federated Hermes Inc. decreased its holdings in Xencor, Inc. (NASDAQ:XNCR) by 58.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,436 shares of the biopharmaceutical company’s stock after selling 3,467 shares during the quarter. Federated Hermes Inc.’s holdings in Xencor were worth $52,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in XNCR. Raymond James Financial Services Advisors Inc. grew its holdings in Xencor by 4.5% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 16,781 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 718 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Xencor by 24.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,575 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 2,431 shares during the period. BluePath Capital Management LLC purchased a new stake in shares of Xencor during the 3rd quarter worth about $31,000. Inspire Investing LLC purchased a new stake in shares of Xencor during the 3rd quarter worth about $308,000. Finally, TD Asset Management Inc grew its holdings in shares of Xencor by 57.6% during the 3rd quarter. TD Asset Management Inc now owns 180,164 shares of the biopharmaceutical company’s stock worth $3,630,000 after purchasing an additional 65,825 shares during the period.

Insider Buying and Selling

In related news, CEO Bassil I. Dahiyat sold 12,528 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total transaction of $293,531.04. Following the transaction, the chief executive officer now directly owns 300,097 shares in the company, valued at $7,031,272.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Bassil I. Dahiyat sold 12,528 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total transaction of $293,531.04. Following the transaction, the chief executive officer now directly owns 300,097 shares in the company, valued at $7,031,272.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP John R. Desjarlais sold 54,108 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the transaction, the vice president now owns 161,675 shares in the company, valued at $3,133,261.50. The disclosure for this sale can be found here. Insiders have sold 101,351 shares of company stock worth $2,152,417 over the last ninety days. 5.23% of the stock is owned by insiders.

Xencor Stock Performance

Xencor stock opened at $24.31 on Tuesday. The stock has a market cap of $1.50 billion, a P/E ratio of -11.58 and a beta of 0.77. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $21.85 and a 200-day moving average of $20.54. Xencor, Inc. has a 52 week low of $16.49 and a 52 week high of $28.96.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.67). Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The firm had revenue of $44.70 million for the quarter, compared to the consensus estimate of $77.63 million. During the same quarter last year, the business earned ($0.20) earnings per share. The business’s revenue for the quarter was up 106.9% compared to the same quarter last year. On average, analysts expect that Xencor, Inc. will post -3.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

XNCR has been the subject of a number of research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $32.00 target price on shares of Xencor in a report on Wednesday, February 28th. BMO Capital Markets decreased their price target on Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Piper Sandler restated a “neutral” rating and issued a $24.00 price target (down previously from $37.00) on shares of Xencor in a report on Wednesday, February 28th. StockNews.com upgraded Xencor from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. Finally, Mizuho decreased their price target on Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a report on Monday, January 22nd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Xencor currently has an average rating of “Moderate Buy” and an average target price of $36.00.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.